Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Ireland
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company's growing biologics portfolio.
AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA®) in rare emergency situations such as urgent surgery, or in the event of major bleeding.
Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China. The new manufacturing site sets out to address the continuously growing demand for diagnostic tests in China and the Asia Pacific region.
Bayer operationally strong - strategic focus on Life Science businesses
- Details
- Category: Bayer
Sales of the Bayer Group rose by 5.6 percent in the third quarter of 2014 to EUR 10,187 million (Q3 2013: EUR 9,643 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales grew by 7.4 percent. EBIT rose by 12.7 percent to EUR 1,376 million (Q3 2013: EUR 1,221 million).
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
- Details
- Category: AstraZeneca
AstraZeneca has launched a programme aimed at tackling the burden of hypertension in Africa. Healthy Heart Africa is designed in consultation and collaboration with non-governmental and community based organisations, international organisations, health experts and governments to support local health systems by increasing awareness of the symptoms and risks of hypertension and offering education, screening, treatment and control.
Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and F-star Alpha Ltd. have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire F-star Alpha Ltd, and gain worldwide rights to its lead asset FS102.
AstraZeneca strengthens partnership with the University of Cambridge
- Details
- Category: AstraZeneca
AstraZeneca, together with its global biologics research and development arm, MedImmune, has entered into four new collaborations with the University of Cambridge, building further on their existing partnership.
More Pharma News ...
- Roche delivers solid sales growth for the first nine months of 2014
- Novo Nordisk second best science employer in the world
- Bayer supports World Thrombosis Day as founding global partner
- Positive results from Phase IIb benralizumab study in severe asthma
- New data on the global economic impact and burden of preventable blindness and vision impairment
- GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund
- Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC